.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Accenture
Mallinckrodt
Moodys
Harvard Business School
Johnson and Johnson
Fuji
Chinese Patent Office
Medtronic
Cantor Fitzgerald

Generated: December 15, 2017

DrugPatentWatch Database Preview

Osi Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for OSI PHARMS, and when can generic versions of OSI PHARMS drugs launch?

OSI PHARMS has one approved drug.

There are four US patents protecting OSI PHARMS drugs.

There are one hundred and nineteen patent family members on OSI PHARMS drugs in fifty countries and nine supplementary protection certificates in eight countries.

Summary for Osi Pharms

International Patents:119
US Patents:4
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-002Nov 18, 2004RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-003Nov 18, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-002Nov 18, 2004RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-002Nov 18, 2004RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-001Nov 18, 2004RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-003Nov 18, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-003Nov 18, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-002Nov 18, 2004RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-003Nov 18, 2004RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-002Nov 18, 2004RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for OSI PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
erlotinib hydrochlorideTablets25 mg, 100 mg and 150 mgTARCEVA11/18/2008

International Patent Family for Osi Pharms Drugs

Country Document Number Estimated Expiration
Malaysia117896► Subscribe
Luxembourg91209► Subscribe
Hong Kong1049663► Subscribe
European Patent Office2168581► Subscribe
Canada2216796► Subscribe
Japan3088018► Subscribe
China1066142► Subscribe
New Zealand286263► Subscribe
Brazil9601200► Subscribe
Canada2389333► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Osi Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2006Austria► SubscribePRODUCT NAME: ERLOTINIB UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE ERLOTINIBHYDROCHLORID; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 - EU/1/05/311/003 20050919; FIRST REGISTRATION: CH 57266 01 - 57266 03 20050321
0214Netherlands► Subscribe300214, 20150606, EXPIRES: 20200320
C001/2006Ireland► SubscribeSPC001/2006: 20070817, EXPIRES: 20200320
C/GB06/008United Kingdom► SubscribePRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919
2006 00006Denmark► Subscribe
0817775/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
00214Netherlands► SubscribePRODUCT NAME: ERLOTINIB, DESGEWENST IN DE; REGISTRATION NO/DATE: 57266 01,..02,..03EU/1/05/311/001...003 20050321
209Luxembourg► Subscribe91209, EXPIRES: 20200321
C0010France► SubscribePRODUCT NAME: ERLOTINIB HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 20050919; FIRST REGISTRATION: LI - 57266 20050321
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Argus Health
Moodys
McKinsey
McKesson
Julphar
Federal Trade Commission
Cipla
Merck
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot